Membrane stabilizing activity and beta-adrenoceptor antagonist-induced bradycardia in conscious dogs.
The atrial effective refractory period (AERP) and atrial and ventricular chronotropic effects of the stereoisomers of propranolol, pindolol, metoprolol and penbutolol were studied in conscious atrio-ventricular blocked dogs. Atrial beta-adrenoceptor blocking activity was assessed for all the drugs against isoprenaline. All the drugs except dextro-pindolol lengthened AERP and decreased ventricular rate dose relatedly. At comparable levels of atrial beta-adrenoceptor blockade, dextro-propranolol, dextro-metoprolol and dextro-penbutolol were more potent to induce AERP lengthening than their respective levo-isomers, whereas dextro-pindolol was less potent than levo-pindolol. In addition, levo-pindolol and levo-metoprolol were more potent to produce ventricular bradycardia than the corresponding dextro-isomers, whereas the levo- and dextro-isomers of propranolol and penbutolol were equipotent. These results confirm that the ventricular bradycardia induced by the different beta-adrenoceptor antagonists is partly due to ventricular beta-adrenoceptor blockade and to the membrane stabilizing activity of these drugs, and partly to another as yet unknown factor seen especially with the levo-isomers and particularly marked with metoprolol.
Boucher
M
M
U.195 INSERM, Faculty of Medicine, Clermont-Ferrand, France.
Chapuy
E
E
Duchêne-Marullaz
P
P
D000319:Adrenergic beta-Antagonists / Q000493:pharmacokinetics / Q000494:pharmacology*; D000818:Animals; D016275:Atrial Function; D001919:Bradycardia / Q000139:chemically induced; D003243:Consciousness; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D005260:Female; D006325:Heart Atria / Q000187:drug effects / Q000648:ultrastructure; D006327:Heart Block; D006339:Heart Rate / Q000187:drug effects*; D006352:Heart Ventricles / Q000187:drug effects / Q000648:ultrastructure; D008297:Male; D008566:Membranes / Q000187:drug effects / Q000378:metabolism; D008790:Metoprolol / Q000493:pharmacokinetics / Q000494:pharmacology; D010394:Penbutolol / Q000493:pharmacokinetics / Q000494:pharmacology; D010869:Pindolol / Q000493:pharmacokinetics / Q000494:pharmacology; D011433:Propranolol / Q000493:pharmacokinetics / Q000494:pharmacology; D012032:Refractory Period, Electrophysiological / Q000187:drug effects*; D013237:Stereoisomerism; D016276:Ventricular Function
D000319:Adrenergic beta-Antagonists; D010394:Penbutolol; D011433:Propranolol; D010869:Pindolol; D008790:Metoprolol